December 18, 2019Seeking Alpha
RITUXAN
is a Private company. RITUXAN has an estimated revenue of <$1M and an estimate of less <10 employees.RITUXAN
is a Private company. RITUXAN has an estimated revenue of <$1M and an estimate of less <10 employees.
CEO
Add
News
Dec 18, 2019
Seeking Alpha
RITUXAN: Canada sets reimbursement for AbbVie's Venclexta for CLL
Nov 07, 2019
pharmaphorum
RITUXAN: First Rituxan biosimilar Truxima set to make its debut in US
Oct 14, 2019
BioPortfolio
RITUXAN: Rituxan hits targets in latestage pemphigus vulgaris trial
Oct 09, 2019
The Pharma Letter
RITUXAN: Humira and Rituxan cited as costliest price hikes unsupported by new clinical evidence
Oct 07, 2019
Pharamceutical Technology
RITUXAN: Rituxan gains label expansion to two rare forms of pediatric vasculitis
Sep 27, 2019
PharmaLive
RITUXAN: FDA Approves Genentech's Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders
Jun 14, 2019
BioPortfolio
RITUXAN: Rituxan hits endpoints in latestage skin disease trial
Dec 05, 2018
The Pharma Letter
RITUXAN: Imbruvica and Rituxan improve survival in CLL
Nov 30, 2018
Pharmabiz
RITUXAN: US FDA approves Truxima as first biosimilar to Rituxan for NHL treatment
Nov 28, 2018
StreetInsider
Press Release: RITUXAN : FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma
RITUXAN News
November 7, 2019pharmaphorum
First Rituxan biosimilar Truxima set to make its debut in US
Biosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to ... See more »
October 14, 2019BioPortfolio
Rituxan hits targets in latestage pemphigus vulgaris trial
The study is still ongoing with patients participating in a 48week safety followup period.... See more »
RITUXAN Press Releases
November 28, 2018StreetInsider
FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma
The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar... See more »
September 17, 2017PR Newswire
AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA /VENCLYXTO (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
NORTH CHICAGO, Ill., Sept. 18, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and develo... See more »
RITUXAN Headquarters
RITUXAN Summary
ABOUT
Website
rituxan.comCompetitors
There are no competitors identified for RITUXANAcquisitions
There have been no acquisitions found related to RITUXANFunding
Funding data cannot be found related to RITUXANInvestments
Recent investment data cannot be found related to RITUXANFrequently Asked Questions about RITUXAN
How much revenue does RITUXAN generate?
RITUXAN generates $ < 1M in revenueHow much funding does RITUXAN have?
RITUXAN has historically raised $0 in funding
How many employees does RITUXAN have?
RITUXAN has 0 employees